Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats.

Authors:
Woodburn KW; Holmes CP; Wilson SD; Fong KL; Press RJ and 2 more

Journal:
Xenobiotica

Publication Year: 2011

DOI:
10.3109/00498254.2011.649310

PMCID:
PMC3409459

PMID:
22188389

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Xenobiotica

Abbreviation: Xenobiotica

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Toxicology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regi…
Karatza E; Ismailos G; Karalis V. (2021) - Transparency Score: 2/6
Pyrido[3,4-d]pyrimidin-4(3H)-one metabolism mediated by aldehyde oxidase is blocked by C2-substitut…
Hayes A; Mok NY; Liu M and 9 more (2016) - Transparency Score: 1/6
The metabolism of 4-bromoaniline in the bile-cannulated rat: application of ICPMS ((79/81)Br), HPLC…
Duckett C; McCullagh M; Smith C and 1 more (2015) - Transparency Score: 2/6
The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative …
Aminzadeh MA; Reisman SA; Vaziri ND and 3 more (2013) - Transparency Score: 2/6
Assessment of immunotoxicity using precision-cut tissue slices.
Sewald K; Braun A. (2012) - Transparency Score: 1/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of interest KWW, CPH and YM and YT are employees of Affymax and Takeda Pharmacentical Company, respectively, and are developing peginesatide for treatment of anemia in CKD patients."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025